OCUGENIX
Ocugenix is a therapeutics company focused on the development of cancer immunotherapy drugs intended to treat eye diseases. Its cancer immunotherapy drug is a medicine against drug-resistant bacteria, enabling doctors to perform a cancer-related eye treatment.
OCUGENIX
Industry:
Biotechnology Health Care Medical Therapeutics
Founded:
2015-01-01
Address:
Pittsburgh, Pennsylvania, United States
Country:
United States
Website Url:
http://www.ocugenix.com
Total Employee:
1+
Status:
Active
Contact:
412-600-6379
Email Addresses:
[email protected]
Total Funding:
150 K USD
Technology used in webpage:
Viewport Meta IPhone / Mobile Compatible Google Font API Google Analytics Apple Mobile Web Clips Icon Google Tag Manager WordPress Font Awesome Global Site Tag Sitelinks Search Box
Current Employees Featured
Investors List
Innovation Works
Innovation Works investment in Seed Round - Ocugenix
Innovation Works
Innovation Works investment in Seed Round - Ocugenix
Innovation Works
Innovation Works investment in Convertible Note - Ocugenix
Official Site Inspections
http://www.ocugenix.com
- Host name: box5675.bluehost.com
- IP address: 162.241.252.14
- Location: Provo United States
- Latitude: 40.2342
- Longitude: -111.6442
- Metro Code: 770
- Timezone: America/Denver
- Postal: 84606
More informations about "Ocugenix"
Ocugenix: Therapies for Angio-Fibrotic Disease
Ocugenix was founded by a nationally recognized research team from the University of Pittsburgh Medical Center and is based on over 20 years of NIH-funded research into the molecular mechanisms of wound healing and cellular …See details»
Ocugenix - Crunchbase Company Profile & Funding
Ocugenix is a therapeutics company focused on the development of cancer immunotherapy drugs intended to treat eye diseases. Its cancer …See details»
About - Ocugen
Dr. Kompella is an Ocugen Co-founder and a member of the board. He is a Professor of Pharmaceutical Sciences, Ophthalmology, and Bioengineering at University of Colorado …See details»
Ocugenix Company Profile | Management and Employees List
Ocugenix focuses on developing therapies for angio-fibrotic diseases of the eye by utilizing the body's natural healing mechanisms to reverse chronic inflammation and restore homeostasis. …See details»
Ocugenix 2025 Company Profile: Valuation, Funding
Ocugenix General Information Description. Developer of cancer immunotherapy therapeutics designed for ocular diseases. The company develops immunotherapy small molecule drugs which is a medicine against drug …See details»
Ocugenix Corp. - Drug pipelines, Patents, Clinical trials - Synapse
May 8, 2025 Explore Ocugenix Corp. with its drug pipeline, therapeutic area, technology platform, 1 clinical trial, 3 news, Technology Platform:Small molecule drug, Drug:OCU-10-C …See details»
Ocugenix - Overview, News & Similar companies | ZoomInfo.com
Ocugenix is a therapeutics company focused on the development of of cancer immunotherapy drug intended to treat eye diseases. Its cancer immunother apy drug is a medicine against …See details»
Ocugenix - 2025 Company Profile, Funding & Competitors - Tracxn
May 8, 2025 Ocugenix has raised $100K in funding from Innovation Works. The company has 16 active competitors, including 8 funded and 1 that has exited. Its top competitors include …See details»
Pitt Startup Check-in: Ocugenix - University of Pittsburgh
Oct 31, 2023 Prior to launching Ocugenix, McDonald enjoyed success as co-founder of Pittsburgh-based Automated Healthcare Inc, the first robotic medication dispensing system for …See details»
Ocugenix Company Profile | Pittsburgh, PA - Dun & Bradstreet
Ocugenix Company Profile | Pittsburgh, PA | Competitors, Financials & Contacts - Dun & BradstreetSee details»
Ocugenix - Funding, Financials, Valuation & Investors - Crunchbase
Ocugenix is a therapeutics company that develops treatments for angio-fibrotic diseases of the eye. New. Resources. ... Experience the new Crunchbase, powered by AI . Experience the …See details»
Ocugenix: Therapies for Angio-Fibrotic Disease
Ocugenix is focused on the development and commercialization of therapeutics for ocular diseases caused by excessive fibrosis and blood vessels in the eye. The Company’s lead …See details»
Ocugen - Crunchbase Company Profile & Funding
Ocugen is a clinical-stage biopharmaceutical company focused on discoverinOcugen Inc is a clinical-stage biopharmaceutical business focused on discovering, developing, and …See details»
Ocugen Inc. - Patient-Centric Biotechnology
At Ocugen, we are focused on discovering, developing, and commercializing novel gene and cell therapies and vaccines that improve health and offer hope for patients across the globe. Our …See details»
Ocugenix - Innovation Works
Ocugenix is developing therapies for angio-fibrotic diseases of the eye such as wet macular degeneration and diabetic retinopathy. These diseases are caused by an aberrant wound …See details»
Pitt Startup Check-in: Ocugenix
Oct 31, 2023 While the development journey for Ocugenix has taken several years, this is not atypical as the average drug takes between 10 and 15 years. “We have been very efficient in …See details»
Ocugen, Inc. Announces Health Canada Approval to Initiate Phase …
MALVERN, Pa., Aug. 26, 2024 (GLOBE NEWSWIRE) -- Ocugen, Inc. (“Ocugen” or the “Company”) (NASDAQ: OCGN), a biotechnology company focused on discovering, …See details»
Ocugenix - Updates, News, Events, Signals & Triggers - Crunchbase
Ocugenix is a therapeutics company that develops treatments for angio-fibrotic diseases of the eye. New. Resources. Advanced Search. Start Free Trial . Talk With Sales. Pricing. Log In. …See details»
Ocugenix - Contacts, Employees, Board Members, Advisors
Ocugenix is a therapeutics company that develops treatments for angio-fibrotic diseases of the eye. New. Resources. Advanced Search. Start Free Trial . Talk With Sales. Pricing. Log In. …See details»
OCU 110 - AdisInsight - Springer
Nov 24, 2023 OCU 110 is a small molecule that selectively activates the CXCR3 pathway, being developed by Ocugenix for the treatment of neovascular age-related macular OCU 110 Next …See details»